Adjuvant Global Health Technology Fund, L.p. - Net Worth and Insider Trading

Adjuvant Global Health Technology Fund, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Adjuvant Global Health Technology Fund, L.p. owns 1 companies in total, including AN2 Therapeutics Inc (ANTX) .

Click here to see the complete history of Adjuvant Global Health Technology Fund, L.p.’s form 4 insider trades.

Insider Ownership Summary of Adjuvant Global Health Technology Fund, L.p.

Ticker	Comapny	Transaction Date	Type of Owner
ANTX	AN2 Therapeutics Inc	2022-03-24	10 percent owner

Adjuvant Global Health Technology Fund, L.p. Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Adjuvant Global Health Technology Fund, L.p. Ownership Network

Ownership Network List of Adjuvant Global Health Technology Fund, L.p.

No Data

Ownership Network Relation of Adjuvant Global Health Technology Fund, L.p.

Adjuvant Global Health Technology Fund, L.p. Owned Company Details

What does AN2 Therapeutics Inc do?

Who are the key executives at AN2 Therapeutics Inc?

Adjuvant Global Health Technology Fund, L.p. is the 10 percent owner of AN2 Therapeutics Inc. Other key executives at AN2 Therapeutics Inc include 10 percent owner Adjuvant Global Health Technology Fund De, L.p. , Chief Strategy Officer Kevin Michael Krause , and director & Chief Executive Officer Eric Easom .

AN2 Therapeutics Inc (ANTX) Insider Trades Summary

Over the past 18 months, Adjuvant Global Health Technology Fund, L.p. made no insider transaction in AN2 Therapeutics Inc (ANTX). Other recent insider transactions involving AN2 Therapeutics Inc (ANTX) include a net sale of 223,880 shares made by Adjuvant Global Health Technology Fund De, L.p. , a net sale of 223,880 shares made by Kabeer Aziz , and a net sale of 10,000 shares made by Kevin Michael Krause .

In summary, during the past 3 months, insiders sold 0 shares of AN2 Therapeutics Inc (ANTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 565,631 shares of AN2 Therapeutics Inc (ANTX) were sold and 1,787,778 shares were bought by its insiders, resulting in a net purchase of 1,222,147 shares.

AN2 Therapeutics Inc (ANTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

AN2 Therapeutics Inc Insider Transactions

No Available Data

Adjuvant Global Health Technology Fund, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Adjuvant Global Health Technology Fund, L.p.. You might contact Adjuvant Global Health Technology Fund, L.p. via mailing address: C/o Adjuvant Capital, L.p., 501 Fifth Avenue, Suite 1404, New York Ny 10017.

Discussions on Adjuvant Global Health Technology Fund, L.p.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.